AstraZeneca PLC has announced that its medication Ultomiris (ravulizumab) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. This approval is a significant milestone for AstraZeneca and highlights the company's commitment to addressing rare diseases through innovative therapies.

Ultomiris is the first and only C5 complement inhibitor approved for reducing proteinuria in patients with IgAN, a rare kidney disease that can lead to chronic kidney disease and potentially end-stage kidney disease. The approval is based on positive results from the I CAN Phase III trial, where Ultomiris demonstrated a 43.4% reduction in proteinuria compared to placebo at 34 weeks.

Background

AstraZeneca PLC, a large accelerated filer incorporated in the United Kingdom, operates in the pharmaceutical preparations sector (SIC: 2834). The company is listed on the New York Stock Exchange under the ticker symbol AZN. AstraZeneca focuses on the discovery, development, and commercialization of prescription medicines across various therapeutic areas, including oncology and rare diseases.

What the Filing Says

The recent SEC filing states, "Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy." This approval follows a prespecified interim analysis of the I CAN Phase III trial, which showed significant efficacy in reducing protein levels in urine.

Impact

This approval may significantly impact patients suffering from IgAN, offering them a new treatment option that targets a central driver of kidney inflammation. Additionally, it may influence other pharmaceutical companies in the sector to innovate and develop new therapies for similar conditions.

What's Next

Following this approval, AstraZeneca plans to present late-breaking results from the I CAN Phase III trial at the American Society of Nephrology’s Kidney Week 2026. Regulatory submissions based on these interim results are also under review in Japan and other countries.